drugset

drugset / Trial / NCT00620555

A Phase III Open-Label Extension Study Of Gabapentin As Adjunctive Therapy In Japanese Pediatric Patients With Partial Seizures

NCT00620555 ↗

Phase 3 Completed 65 enrolled Viatris Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Examine the safety and efficacy of gabapentin as adjunctive therapy in Japanese pediatric patients with partial seizures

Timeline

Start: 2008-05
Primary completion: 2010-12
Completion: 2010-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Gabapentin	Small molecule	—	Oral

Indications